This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
A total of 1000 adults were enrolled in the study, 999 were vaccinated with PCV13 and 993 completed the study. The median age of the study population at the time of vaccination was 57.4 years, and 58.6% of the participants were men.
Among the participants, 400 were randomised to the immunogenicity subset, and 388 were included in the immunogenicity analysis population. None of the participants had immunisation history with PPSV23 or any other pneumococcal vaccine.
Analysis of the immune responses showed a significant increase in the OPA GMTs for all 13 serotypes. This increase was observed from before to approximately 1 month after vaccination. The lower limit of the 2-sided 95% CI for the GMFR was >1.1
Serious adverse events or deaths were not reported. Moreover, no adverse event led to the withdrawal of the participant from the study.
GMFR of Pneumococcal OPA GMTs Prior to and 1 Month After PCV13 Vaccination
GMFR of Pneumococcal OPA GMTs Prior to and 1 Month After PCV13 Vaccination
Adapted from Solanki BB, et al. 2017.
CI, confidence interval; GMFR, geometric mean fold rise; GMT, geometric mean titre; OPA, opsonic pneumococcal antibody; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.
Reference:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0661 July 2023
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
FAQs related to different fields
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.